Risk Factor-Driven Upstream Therapy Improves Sinus Rhythm for AFib Patients
The novel therapy showed sinus rhythm was present in 75% of patients after 1-year follow-up.
Read More
Benznidazole Granted Accelerated FDA Approval to Treat Chagas Disease
The drug is the first treatment approved in the US for Chagas disease.
Abbott Issues Software Update Amid Risk of Pacemaker Hacking
There are currently no known reports of patient harm for the 465,000 implanted devices in question, according to the FDA.
Anacetrapib Reduced Risk of Cardiovascular Events
Merck's drug showed a 9% reduction in risk of major cardiovascular events in the REVEAL trial.
Canakinumab Cuts Cardiovascular Risk Via Reduced Inflammation
The drug was found to be most effective in its 150 mg and 300 mg doses, reducing cardiovascular events by 15% and 14%, respectively.
Less REM Sleep Linked to Heightened Dementia Risk
For every percentage of REM sleep loss, the risks of dementia increased 9%.
Catheter Ablation Lowers AFib Mortality, Hospitalization Rates
Catheter ablation lowered mortality rates to 13.4% and hospitalization rates to 20.7%, significant decreases compared to the conventional methods.
Heightened Risk of Hemorrhagic Stroke Linked to Methamphetamine Use
Methamphetamine was found to be linked to hemorrhagic strokes in 80% of cases.
Short-Term Removal of Sugar Reduces Sugar-to-Fat Conversion in Liver
In just 9 days of limited fructose consumption, both liver fat concentration and de novo lipogensis decreased.
FDA Approves Liraglutide for Cardiovascular Risk
Liraglutide showed a 13% reduction in major adverse cardiovascular events, reduced cardiovascular morbidity by 22%, and any morbidity by 15%.
Extended Ticagrelor Shows Cardiovascular Risk Reduction
The drug showed a 29% reduction in risk for patients who had a myocardial infarction.
US, EU Aim to Strengthen Medical Inspection Cooperation
The 2 entities reached an agreement allowing for the full sharing of trade secret information relating to medicine inspections.
FDA Grants Priority Review to Emicizumab for Haemophilia A Treatment
The drug will be reviewed based on the results of the phase 3 HAVEN 1 and 2 studies.
Continuous Glucose Monitoring Positive for Type 2 Diabetes Patients
CGM has shown to be beneficial to T2D patients who utilize it, although barriers may prevent widespread use.
3.2 Million COPD Deaths Worldwide in 2015
COPD-related deaths increased 11.6% since 1990, and cases increased 44.2% to 174.5 million.
David Boyer: ALG-1001 vs. Bevacizumab
David Boyer, MD, talks about the topline results from a prospective, double-masked phase 2b clinical trial evaluating ALG-1001 compared to Bevacizumab in patients with DME.
Raj Maturi: Sirolimus in Conjunction With Aflibercept
Raj Maturi, MD, talks about the use of sirolimus in combination with aflibercept for patients with chronic AMD.
Type 2 Diabetes Patients Need Therapy Intensification Sooner
The study highlighted the need to intensify treatment for glycemic control sooner than current methods suggest.
Aflibercept Aids Visual Acuity in PROMISE Study
The phase 2 trial results were very positive in regards to its safety endpoints and the efficacy endpoints were very encouraging.
Jay Prensky: The PALADIN Real-World Observational Study
Jay Prensky, MD, talks about the results of the PALADIN real-world study and the use of the fluocinolone acetonide 0.2 ug/day implant in DME patients.
Carl Baker: Panretinal Photocoagulation vs. Ranibizumab for Diabetic Retinopathy Treatment
Carl Baker, MD, speaks about factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or Ranibizumab.
Rishi Singh: Aflibercept Use for DME Patients and the PROMISE Study Results
Rishi Singh, MD, talks about the prevention of macular edema in patients with diabetic retinopathy undergoing cataract surgery with an intravitreal aflibercept injection.
Jay Prensky: Real-World Studies vs. Clinical Trials
Jay Prensky, MD, talks about the pluses and clinical implications of doing real-world observational studies as opposed to clinical trials.
Rishi Singh: We Need a Standard Definition for DME
Rishi Singh, MD, talks about the need for a standard definition of identifying macular edema in diabetic patients.
Thomas Ciulla: Real-World Outcomes for DME Patients
Thomas Ciulla speaks about the “real-world” outcomes for anti-VEGF therapy in patients with diabetic macular edema (DME) in the United States.
Rajeev Muni: Pneumatic Retinopexy vs. Vitrectomy
Rajeev Muni speaks about the 1-year results of a randomized trial comparing Pneumatic Retinopexy vs. Vitrectomy in the management of primary Rhegmatogenous Retinal Detachment.
Aflibercept Similar to Ranibizumab in Visual Acuity Improvements in VIEW Studies
In an analysis of dosing subgroups through 96 weeks of the VIEW 1 and 2 trials, aflibercept injections showed similar results in meeting visual acuity endpoints to ranibizumab.
FDA to Decide on Liraglutide Use for Cardiovascular Risk
The drug will receive a ruling on Aug. 25. It's currently approved to treat type 2 diabetes and obesity.
Pravin U Dugel: Intravitreal OPT-302 Study Results
Pravin Dugel, MD, talks about the study results for OPT-302 and the possibilities that further data could provide for DME, nAMD, and diabetic retinopathy.
Jeffrey Luttrull: Subthreshold Diode Micropulse Laser
Jeffrey Luttrull, MD, speaks about the reduced risk of choroidal neovascularization following use of the subthreshold diode micropulse laser (SDM) retinal protective therapy™ (RPT) for patients with Dry AMD.